Stock comparison
Collegium Pharmaceutical
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
COLL
Collegium Pharmaceutical
Market cap
$1.11B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | COLL | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 46D | 69B | MTD |
| Benjamin Graham | 62D | 65B | MTD |
| Philip Fisher | 40D | 63C | MTD |
| Peter Lynch | 53D | 66B | MTD |
| Joel Greenblatt | 28F | 68B | MTD |
| Charlie Munger | 44D | 74B | MTD |
| Terry Smith | 43D | 70B | MTD |
Side-by-side metrics
| Metric | COLL | MTD |
|---|---|---|
| Market cap | $1.11B | $22.29B |
| P/E (TTM) | 15.5x | 25.3x |
| EV/EBIT | 9.1x | 21.6x |
| ROIC (TTM) | 10.51% | 36.09% |
| Gross margin | 60.68% | 57.79% |
| Net margin | 9.41% | 21.4% |
| Revenue CAGR 5y | 29.58% | 2.01% |
| EPS CAGR 5y | -0.86% | 6.12% |
| Debt / Equity | 2.6x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
COLL leads on
- Revenue CAGR 5y29.58%vs 2.01%+93%
- EV/EBIT9.1xvs 21.6x+58%
- P/E (TTM)15.5xvs 25.3x+39%
MTD leads on
- EPS CAGR 5y6.12%vs -0.86%+114%
- Debt / Equity-vs 2.6x+105%
- Market cap$22.29Bvs $1.11B+95%
- ROIC (TTM)36.09%vs 10.51%+71%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.